Study to Develop a Breath Analyser to Detect Chronic Kidney Disease

Pilot Study to Develop a Breath Analyser to Detect Chronic Kidney Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03303222

Enrollment

100

Registered

2017-10-05

Start date

2021-02-10

Completion date

2023-11-30

Last updated

2020-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Diseases

Brief summary

Measure trimethylamine oxide in the breath.

Detailed description

Organic compounds such as trimethylamine oxide (TMAO) accumulate in the blood of patients with kidney disease, and volatile compounds such as TMAO can be detected in the breath. The investigators wish to develop a breath analyser to measure volatile compounds, such as TMAO in the breath in patients with kidney disease.

Interventions

DIAGNOSTIC_TESTbreath

measurement of volatile compounds, such as TMAO in exhaled breath and blood

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* patients with kidney disease under the care of Royal Free Hospital

Exclusion criteria

* patients unable to provide informed consent * patients unable to exhale into breath analyser

Design outcomes

Primary

Measure	Time frame	Description
measurement of breath TMAO	3 years	measurement of breath TMAO by breath analyser

Contacts

Primary Contactandrew davenport, md

andrewdavenport@nhs.net442077940500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026